Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on the Pharmacokinetics of AZ14170132 in Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT07402915Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of AZD5335 in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by AstraZeneca. Primary endpoints: Area under curve from time 0 to time 17 days and Maximum plasma drug concentration at Cycle 3. Started Jan 2026; status: recruiting.
02
Drugs
AZD5335
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07402915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402915.